Fda

Edit

Legal questions swirl around FDA's new expedited drug program

Telegraph Herald 18 Jan 2026

WASHINGTON — A plan to slash drug review times at ...

Edit

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Sierra County Sentinel 17 Jan 2026

Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation ... .

Edit

FDA efforts to hasten reviews draw concern

NWA Online 17 Jan 2026

.

Edit

Infant formula recall: FDA reviews 25 cases linked to recall

The Philadelphia Inquirer 17 Jan 2026

MANILA – The Food and Drug Administration (FDA) confirmed receiving 25 reports related to the voluntary recall of certain batches of Nan ...

Edit

FDA deletes content saying cellphones are harmless as HHS launches new study

Sott 17 Jan 2026

Without fanfare, the Food and Drug Administration has deleted multiple web pages asserting that cellphones are not dangerous ... HHS Secretary Robert F ... "There's cellphone tumors ... ....

Edit

Legal questions swirl around FDA's new expedited drug program, including who should sign off

Newsday 17 Jan 2026

Traditionally, approval decisions have nearly always been handled by FDA review scientists and their immediate supervisors, not the agency’s political appointees and senior leaders.

Edit

FDA confirms 25 reports tied to recalled infant formula

The Philadelphia Inquirer 17 Jan 2026

MANILA, Philippines – The Food and Drug Administration (FDA) confirmed receiving 25 reports related to the ... The FDA said it […]...

Edit

FDA receives 25 cases of infant formula recall

The Manila Times 17 Jan 2026

THE Food and Drug Administration (FDA) has confirmed receiving 25 reports related to the voluntary recall of certain batches of Nan Optipro and Nankid Optipro infant formula products ... Concerns may also be reported via ereport@fda.gov.ph.

Edit

Takeaways from the AP's report on turmoil surrounding the FDA's new fast-track drug program

Newsday 17 Jan 2026

The initiative by FDA Commissioner Marty Makary promises ultra-fast reviews for drugs that align with “U.S ... But FDA staffers say the push for faster approvals is contributing to a climate of anxiety, ...

Edit

Proprio's Fourth FDA Clearance Highlights Growing Shift to 3D Measurement in Spine Care

Independent Record 16 Jan 2026

Picasso Experience Expands Surgeon-Controlled, Radiation-Free Registration Workflows for Real-Time Intraoperative Spinal Alignment Measurements ... .

Edit

Legal questions swirl around FDA\u2019s new expedited drug program, including who should sign off

Standard-Speaker 16 Jan 2026

.

Edit

Legal Questions Swirl Around FDA’s New Expedited Drug Program, Including Who Should Sign Off

The National Herald 16 Jan 2026

WASHINGTON (AP) — The Food and Drug Administration ...

Edit

Takeaways from the AP’s report on turmoil surrounding the FDA’s new fast-track drug program

The Seattle Times 16 Jan 2026

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on drugs cleared under a new plan to slash FDA drug review times ... .

Edit

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, ...

Nasdaq Globe Newswire 16 Jan 2026

Investors who lost money in CORT after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman ... .

Edit

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response

Enid News & Eagle 16 Jan 2026

SAN FRANCISCO, Jan.

Podcasts:

Latest News for: fda

Legal questions swirl around FDA's new expedited drug program

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

FDA efforts to hasten reviews draw concern

Infant formula recall: FDA reviews 25 cases linked to recall

FDA deletes content saying cellphones are harmless as HHS launches new study

Legal questions swirl around FDA's new expedited drug program, including who should sign off

FDA confirms 25 reports tied to recalled infant formula

FDA receives 25 cases of infant formula recall

Takeaways from the AP's report on turmoil surrounding the FDA's new fast-track drug program

Proprio's Fourth FDA Clearance Highlights Growing Shift to 3D Measurement in Spine Care

Legal questions swirl around FDA\u2019s new expedited drug program, including who should sign off

Legal Questions Swirl Around FDA’s New Expedited Drug Program, Including Who Should Sign Off

Takeaways from the AP’s report on turmoil surrounding the FDA’s new fast-track drug program

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, ...

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response

Article Search

EXPLORE WN.com